In July 6^th, Tianjin Sungene held the third board meeting of this year at company headquarter, the participants included company directors and invited representatives. The meeting reported the overall company sales situation in the first and second quarter of 2013. For the first half year of 2013, company's total sales rose 121% over last year; Sales in April tripled over that of the same period last year. In addition, the meeting also reported company financial situation of this year. The company is greatly widening direct and indirect financing through equity financing, secured loans, shareholder loans, etc., a number of financial institutions and potential investors have direct intention of investment and financing.

The board of directors declared project application situation of clinical products currently; It also reported detailed preparation, time schedule, and future sales forecasts of three projects(antibodies of flow cytometry, pathological antibodies, and immune diagnosis kit(ELISA kits)) for each director and attended representative. In the meeting, it decided that the company should adopt standardized on-site management---"5S Management", and considered this in the scope of performance evaluation for the sake of improving company standardized on-site management and further promoting company's large-scale production of biological reagents .